125 related articles for article (PubMed ID: 3041819)
1. Survey of antibiotic susceptibility among gram-negative bacilli at a cancer hospital.
Bodey GP; Ho DH; Elting L
Am J Med; 1988 Jul; 85(1A):49-51. PubMed ID: 3041819
[TBL] [Abstract][Full Text] [Related]
2. Survey of antibiotic susceptibility among gram-negative bacilli at a cancer center.
Rolston KV; Elting L; Waguespack S; Ho DH; LeBlanc B; Bodey GP
Chemotherapy; 1996; 42(5):348-53. PubMed ID: 8874974
[TBL] [Abstract][Full Text] [Related]
3. [Changes of antimicrobial resistance among nonfermenting gram-negative bacilli isolated from intensive care units from 1994 to 2001 in China].
Wang H; Chen MJ;
Zhonghua Yi Xue Za Zhi; 2003 Mar; 83(5):385-90. PubMed ID: 12820914
[TBL] [Abstract][Full Text] [Related]
4. Susceptibility surveillance among gram-negative bacilli at a cancer center.
Jacobson K; Rolston K; Elting L; LeBlanc B; Whimbey E; Ho DH
Chemotherapy; 1999; 45(5):325-34. PubMed ID: 10473920
[TBL] [Abstract][Full Text] [Related]
5. [The reliability of using impenem, meropenem, cefoperazone-sulbactam and piperacillin-tazobactam to treat nosocomial Gram-negative bacterial infections with Monte Carlo simulation].
Xiao YH; Hu YJ
Zhonghua Nei Ke Za Zhi; 2017 Aug; 56(8):595-600. PubMed ID: 28789493
[No Abstract] [Full Text] [Related]
6. In vitro activity against aerobic and anaerobic gram-positive and gram-negative bacteria and beta-lactamase stability of RS-533, a novel carbapenem.
Neu HC; Chin NX; Saha G; Labthavikul P
Antimicrob Agents Chemother; 1986 Dec; 30(6):828-34. PubMed ID: 3545068
[TBL] [Abstract][Full Text] [Related]
7. Comparative activity of newer antibiotics against gram-negative bacilli.
Knapp CC; Washington JA
Cleve Clin J Med; 1989; 56(2):161-6. PubMed ID: 2731335
[TBL] [Abstract][Full Text] [Related]
8. Multicenter evaluation of the in vitro activity of piperacillin-tazobactam compared with eleven selected beta-lactam antibiotics and ciprofloxacin against more than 42,000 aerobic gram-positive and gram-negative bacteria. In Vitro Susceptibility Surveillance Group.
Murray PR; Cantrell HF; Lankford RB
Diagn Microbiol Infect Dis; 1994 Jun; 19(2):111-20. PubMed ID: 7805355
[TBL] [Abstract][Full Text] [Related]
9. [Continuous surveillance of antimicrobial resistance among nosocomial gram-negative bacilli from intensive care units in China].
Chen MJ; Wang H;
Zhonghua Yi Xue Za Zhi; 2003 Mar; 83(5):375-81. PubMed ID: 12820912
[TBL] [Abstract][Full Text] [Related]
10. In-vitro activity of cefpirome (HR-810), WIN-49375, BMY-28142 and other antibiotics against nosocomially important isolates from cancer patients.
Rolston KV; Alvarez ME; Hsu KC; Bodey GP
J Antimicrob Chemother; 1986 Apr; 17(4):453-7. PubMed ID: 3458694
[TBL] [Abstract][Full Text] [Related]
11. Comparative in vitro antimicrobial activity of carumonam, a new monocyclic beta-lactam.
Smith BR; LeFrock JL; McCloskey RV; Donato JB; Weber SJ; Joseph WS
Antimicrob Agents Chemother; 1986 Feb; 29(2):346-9. PubMed ID: 3087280
[TBL] [Abstract][Full Text] [Related]
12. In vitro activity of piperacillin, ticarcillin, mezlocillin, ticarcillin-clavulanic acid, aztreonam, ceftazidime, azlocillin, cefoperazone, and thienamycin against Pseudomonas aeruginosa.
Greenberg RN; Bollinger MR; Alivisatos MR
Clin Ther; 1986; 8(6):655-7. PubMed ID: 3098426
[TBL] [Abstract][Full Text] [Related]
13. The in-vitro activity of piperacillin/tazobactam, ciprofloxacin, ceftazidime and imipenem against multiple resistant gram-negative bacteria.
Mehtar S; Drabu YJ; Blakemore PH
J Antimicrob Chemother; 1990 Jun; 25(6):915-9. PubMed ID: 2164513
[TBL] [Abstract][Full Text] [Related]
14. Cross-susceptibility of cefpirome and four other beta-lactams against isolates from haematology/oncology and intensive care units. International Study Group.
Spencer RC
Scand J Infect Dis Suppl; 1993; 91():25-32. PubMed ID: 8290900
[TBL] [Abstract][Full Text] [Related]
15. Resistance to beta-lactam antibiotics and ciprofloxacin in gram-negative bacilli and staphylococci isolated from blood: a European collaborative study. European Study Group on Antibiotic Resistance.
Dornbusch K
J Antimicrob Chemother; 1990 Aug; 26(2):269-78. PubMed ID: 2211458
[TBL] [Abstract][Full Text] [Related]
16. Comparison of in vitro activities of ceftazidime, piperacillin-tazobactam, and cefoperazone-sulbactam, and the implication on empirical therapy in patients with cancer.
Prabhash K; Medhekar A; Biswas S; Kurkure P; Nair R; Kelkar R
Indian J Cancer; 2009; 46(4):318-22. PubMed ID: 19749462
[TBL] [Abstract][Full Text] [Related]
17. Antimicrobial susceptibility pattern comparisons among intensive care unit and general ward Gram-negative isolates from the Meropenem Yearly Susceptibility Test Information Collection Program (USA).
Rhomberg PR; Fritsche TR; Sader HS; Jones RN
Diagn Microbiol Infect Dis; 2006 Sep; 56(1):57-62. PubMed ID: 16631338
[TBL] [Abstract][Full Text] [Related]
18. [Analysis of the distribution characteristics and drug resistance of non-fermenting bacterial infection in intensive care unit from 2009 to 2015].
Hao D; Hu Z; Liu X; Sun T; Wang T; Tian H; Wang X
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2016 May; 28(5):439-44. PubMed ID: 29920041
[TBL] [Abstract][Full Text] [Related]
19. Aztreonam: antibacterial activity, beta-lactamase stability, and interpretive standards and quality control guidelines for disk-diffusion susceptibility tests.
Barry AL; Thornsberry C; Jones RN; Gavan TL
Rev Infect Dis; 1985; 7 Suppl 4():S594-604. PubMed ID: 3909316
[TBL] [Abstract][Full Text] [Related]
20. Contemporary activity of meropenem and comparator broad-spectrum agents: MYSTIC program report from the United States component (2005).
Rhomberg PR; Jones RN
Diagn Microbiol Infect Dis; 2007 Feb; 57(2):207-15. PubMed ID: 16949243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
